Reuters logo
BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935
August 21, 2017 / 12:22 PM / a month ago

BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935

Aug 21 (Reuters) - Ovid Therapeutics Inc

* Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below